May 6th 2025
US outbreaks account for 93% of cases, North Dakota sees first case since 2011, and the Americas Region reports over 2,300 infections.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
University Mumps Outbreak Prevails Despite High 2-Dose MMR Coverage
April 27th 2017The University of Iowa experienced a large mumps outbreak last year, despite almost 100% adherence to 2-dose measles, mumps, rubella (MMR) vaccine schedule, which begs the question, is it time to start recommending a 3-dose schedule?
Read More
Active Genital Herpes in Early Pregnancy Linked with Autism Spectrum Disorders
March 29th 2017Researchers have discovered that women who experience active genital herpes infection early in their pregnancy may be more likely to have a child who will later be diagnosed with autism spectrum disorder.
Read More
Ocular Syphilis May Suggest HIV Co-Infection
March 28th 2017Researchers have found that cases of ocular syphilis have been increasing in North Carolina and that the prevalence of ocular syphilis was almost twice as high among HIV-positive patients as among those who were HIV negative or HIV unknown.
Read More
Examining the Bactericidal Behavior of a New MRSA Treatment
March 17th 2017Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.
Watch
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.
Watch
How Effective is TXA709 Against MRSA?
February 16th 2017Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.
Watch